Role of in vitro cholesterol depletion in mediating human platelet aggregation

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 3, 2003, Pages 576-586

  Grgurevich, S ^a,b   Krishnan, R ^a,b   White, M M ^a,b   Jennings, L K ^a,b  

^a Department of Medicine   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Cholesterol; Methyl cyclodextrin; Platelet

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA CYCLODEXTRIN DERIVATIVE; CHOLESTEROL; COLLAGEN; CYCLODEXTRIN; METHYL BETA CYCLODEXTRIN; METHYL-BETA-CYCLODEXTRIN; PHOSPHOPROTEIN; THROMBIN RECEPTOR;

ARTICLE; CELL SIZE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; PHYSIOLOGY; SCANNING ELECTRON MICROSCOPY; SECRETION; THROMBOCYTE; THROMBOCYTE AGGREGATION; ULTRASTRUCTURE;

ADENOSINE TRIPHOSPHATE; BETA-CYCLODEXTRINS; BLOOD PLATELETS; CELL SIZE; CHOLESTEROL; COLLAGEN; CYCLODEXTRINS; HUMANS; MICROSCOPY, ELECTRON, SCANNING; PHOSPHOPROTEINS; PLATELET AGGREGATION; RECEPTORS, THROMBIN;

EID: 0642372603     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00087.x     Document Type: Article

References (49)

1. White MC, Jennings LK. Platelet Protocols: Research and Clinical Laboratory Procedures. Academic Press: San Diego, CA, 1999.
2. Holmsen H. Significance of testing platelet functions in vitro. Eur J Clin Invest 1994; 24: 3-8.
3. Wurzinger LJ. Histophysiology of the circulating platelet. Adv Anat Embryol Cell Biol 1990; 120: 1-96.
4. Payrastre B, Missy K, Trumel C, Bodin S, Plantavid M, Chap H. The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochem Pharmacol 2000; 60: 1069-74.
5. Levy-Toledano S. Platelet signal transduction pathways: could we organize them into a 'hierarchy'? Haemostasis 1999; 29: 4-15.
6. Wiggins BS, Wittkowsky AK, Nappi JM. Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes. Pharmacotherapy 2001; 21: 320-37.
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
8. Dawber TR, Kannel WB. The Framingham study. An epidemiological approach to coronary heart disease. Circulation 1966; 34: 553-5.
9. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
10. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM, Farquhar JW. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994; 89: 975-90.
11. Shattil SJ, Bennett JS, Colman RW, Cooper RA. Abnormalities of cholesterol-phospholipid composition in platelets and low-density lipoproteins of human hyperbetalipoproteinemia. J Lab Clin Med 1977; 89: 341-53.
12. Shastri KM, Carvalho AC, Lees RS. Platelet function and platelet lipid composition in the dyslipoproteinemias. J Lipid Res 1980; 21: 467-72.
13. Carvalho AC, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-8.
14. Chetty N, Naran NH. Platelet hyperreactivity in hyperlipidaemia with specific reference to platelet lipids and fatty acid composition. Clin Chim Acta 1992; 213: 1-13.
15. Zahavi J, Betteridge JD, Jones NA, Galton DJ, Kakkar VV. Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia. Am J Med 1981; 70: 59-64.
16. DiMinno G, Silver MJ, Cerbone AM, Rainone A, Postiglione A, Mancini M. Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia. Arteriosclerosis 1986; 6: 203-11.
17. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, La Placa FP, Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 247-51.
18. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-3.
19. Naqvi TZ, Shah PK, Ivey PA, Molloy MD, Thomas AM, Panicker S, Ahmed A, Cercek B, Kaul S. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol 1999; 84: 1011-7.
20. Shattil SJ, Anaya-Galindo R, Bennett J, Colman RW, Cooper RA. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1975; 55: 636-43.
21. Stuart MJ, Gerrard JM, White JG. Effect of cholesterol on production of thromboxane B2 by platelets in vitro. N Engl J Med 1980; 302: 6-10.
22. Christian AE, Haynes MP, Phillips MC, Rothblat GH. Use of cyclodextrins for manipulating cellular cholesterol content. J Lipid Res 1997; 38: 2264-72.
23. Pitha J, Irie T, Sklar PB, Nye JS. Drug solubilizers to aid pharmacologists: amorphous cyclodextrin derivatives. Life Sci 1988; 43: 493-502.
24. Kilsdonk EPC, Yancey PG, Stoudt GW, Bangerter FW, Johnson WJ, Phillips MC, Rothblat GH. Cellular cholesterol efflux mediated by cyclodextrins. J Biol Chem 1995; 270: 17250-6.
25. Waheed AA, Shimada Y, Heijnen HF, Nakamura M, Inomata M, Hayashi M, Iwashita S, Slot JW, Ohno-Iwashita Y. Selective bindingof perfringolysin O derivative to cholesterol-rich membrane microdomains (rafts). Proc Natl Acad Sci USA 2001; 98: 4926-31.
26. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in procoagulant activity. J Biol Chem 1989; 264: 17049-57.
27. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-7.
28. Ohlmann P, Eckly A, Freund M, Cazenave JP, Offermanns S, Gachet C. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Gaq. Blood 2000; 96: 2134-9.
29. White MM, Foust JT, Mauer AM, Robertson JT, Jennings LK. Assessment of lumiaggregometry for research and clinical laboratories. Thromb Haemost 1992; 67: 572-7.
30. Hussein O, Rosenblat M, Schlezinger S, Keidar S, Aviram M. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 1997; 44: 77-84.
31. Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem 1991; 266: 24302-7.
32. Bearer EL. Cytoskeletal domains in the activated platelet. Cell Motil Cytoskeleton 1995; 30: 50-66.
33. White JG, Clawson CC. The surface-connected canalicular system of blood platelets - a fenestrated membrane system. Am J Pathol 1980; 101: 353-64.
34. Stenberg PE, Shuman MA, Levine SP, Bainton DF. Redistribution of alpha-granules and their contents in thrombin-stimulated platelets. J Cell Biol 1984; 98: 748-60.
35. Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary artey disease - beyond lowering cholesterol. Ann Pharmacother 2000; 34: 1432-9.
36. HeartWire. Biggest-ever statin study will change practice worldwide. http://www.theheart.org/documents/lite/page.cfm?CIOQPKE. Accessed November 13, 2001.
37. Martin JF, Trowbridge EA, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983; 32: 443-60.
38. Pathansali R, Smith N, Bath P. Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia. Platelets 2001; 12: 292-7.
39. Mondoro TH, White MM, Jennings LK. Active GPIIb-IIIa conformations that link ligand interaction with cytoskeletal reorganization. Blood 2000; 96: 2487-95.
40. Escolar G, White JG. Changes in glycoprotein expression after platelet activation: differences between in vitro and in vivo studies. Thromb Haemost 2000; 83: 371-86.
41. Bianciardi G, Weber G, Toti P, Widhalm K, Sinzinger H. Platelet plasma membrane changes in human type IIa hypercholesterolemia. Appl Pathol 1986; 4: 253-9.
42. Bodin S, Giuriato S, Ragab J, Humbel BM, Viala C, Vieu C, Chap H, Payrastre B. Production of phosphatidylinositol 3,4,5-trisphosphate and phosphatidic acid in platelet rafts: evidence for a critical role of cholesterol-enriched domains in human platelet activation. Biochemistry 2001; 40: 15290-9.
43. Gousset K, Wolkers WF, Tsvetkova NM, Oliver AE, Field CL, Walker NJ, Crowe JH, Tablin F. Evidence for a physiological role for membrane rafts in human platelets. J Cell Physiol 2002; 190: 117-28.
44. Opper C, Fett C, Capito B, Raha S, Wesemann W. Plasma membrane properties in heterogeneous human blood platelet subfractions modulate the cellular response at the second messenger level. Thromb Res 1993; 72: 39-47.
45. + antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation 1997; 95: 1370-7.
46. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000; 1: 31-9.
47. Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998; 14: 111-36.
48. Ikonen E. Roles of lipid rafts in membrane transport. Curr Opin Cell Biol 2001; 13: 470-7.
49. Locke D, Chen H, Liu Y, Liu C, Kahn ML. Lipid rafts orchestrate signaling by the platelet receptor glycoprotein VI. J Biol Chem 2002; 277: 18801-9.